Healthcare of Ontario Pension Plan Trust Fund Acquires 1,000,000 Shares of RxSight, Inc. $RXST

Posted by Geri Gentry on Jul 30th, 2026

Healthcare of Ontario Pension Plan Trust Fund lifted its stake in RxSight, Inc. (NASDAQ:RXST – Free Report) by 761.0% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,131,400 shares of the company’s stock after purchasing an additional 1,000,000 shares during the period. Healthcare of Ontario Pension Plan Trust Fund owned 2.73% of RxSight worth $6,969,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RXST. Raymond James Financial Inc. acquired a new position in RxSight in the second quarter valued at about $28,000. Summit Securities Group LLC bought a new stake in shares of RxSight in the first quarter worth $30,000. Larson Financial Group LLC lifted its position in RxSight by 110.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,979 shares of the company’s stock worth $36,000 after buying an additional 2,089 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in RxSight by 440.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company’s stock worth $39,000 after acquiring an additional 3,063 shares in the last quarter. Finally, CWM LLC raised its stake in shares of RxSight by 211.1% during the 4th quarter. CWM LLC now owns 3,826 shares of the company’s stock worth $40,000 after purchasing an additional 2,596 shares in the last quarter. 78.78% of the stock is owned by institutional investors.

RxSight Stock Performance

Shares of RXST opened at $6.13 on Thursday. RxSight, Inc. has a 52 week low of $4.48 and a 52 week high of $13.22. The firm has a market cap of $253.78 million, a P/E ratio of -5.42 and a beta of 1.15. The firm’s 50-day simple moving average is $5.27 and its 200 day simple moving average is $6.80.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on RXST shares. Wells Fargo & Company decreased their target price on shares of RxSight from $11.00 to $9.00 and set an “equal weight” rating for the company in a research note on Thursday, May 7th. Bank of America cut their price target on shares of RxSight from $8.00 to $6.50 and set an “underperform” rating for the company in a research note on Tuesday, July 7th. Wall Street Zen raised shares of RxSight from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. UBS Group restated a “neutral” rating and set a $5.50 price objective (down from $9.00) on shares of RxSight in a research note on Tuesday. Finally, Weiss Ratings cut shares of RxSight from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $8.50.

Get Our Latest Report on RxSight

RxSight Profile

(Free Report)

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.